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Abstract
Recognizing that the current MDR-TB regimen is suboptimal and based on low-quality evidence, the Global MDR-
TB Clinical Trials Landscape Meeting was held in December, 2014 to strategize about coordination of research and
development of new treatment regimens for this disease that affects millions of people worldwide every year. Sixty
international experts on multidrug-resistant tuberculosis (MDR-TB) met in Washington D.C. and Cape Town, South
Africa to consider key MDR-TB trial-related issues, including: standardization of definitions; clinical trial capacity
building and; regimens optimized to foster compliance, avoid the emergence of resistance and have clinical
relevance for special populations, including children and those co-infected with HIV. Underpinning all of this is the
generation of a sufficient evidence base to facilitate regulatory approval and improved normative guidance.
Participants discussed treatment combinations currently being studied in Phase 2B and Phase 3 trials as well as
other promising new regimens and combinations that may be evaluated in the near future. These include
regimens designed specifically to enable shorter duration and all-oral treatment as a means of maximizing
treatment completion. It is hoped that clear definition of these challenges will facilitate the process of identifying
solutions that accelerate progress towards effective, non-toxic treatments that can be programmatically
implemented.
Introduction
According to the World Health Organization (WHO), an
estimated 9 million people developed tuberculosis (TB) in
2013, and 1.5 million died from the disease [1]. Although
the rate of TB has declined modestly in recent years as a
result of effective diagnosis and treatment, multidrug-
resistant TB (MDR-TB) – i.e., TB resistant to the two
most effective first-line drugs, rifampicin and isoniazid –
has not declined and remains a significant global chal-
lenge. The WHO estimates that MDR-TB is responsible
for 3.5% of new and 20.5% of previously-treated TB cases.
Globally, approximately 25% of TB-related mortality is
due to MDR-TB. Additionally, about 9% of MDR-TB
patients have extensively drug resistant TB (XDR-TB),
meaning their TB is also resistant to at least two other sec-
ond-line drugs.
Treatment of MDR-TB requires longer regimens – at
least 20 months – with lower success rates compared to
the treatment of drug sensitive TB (DS-TB) [2]. These
longer regimens, along with a need for enhanced labora-
tory testing and hospitalization, increase the cost and com-
plexity of MDR-TB treatment. The impact of these
differences is particularly profound in high-burden coun-
tries such as South Africa [3]. Drug resistant TB also
threatens the lives of healthcare workers in high-burden
countries [4]. The current MDR-TB regimen is suboptimal
for many reasons: it is based on poor evidence of efficacy
[5], is too long and toxic, includes injectable drugs that
add cost and discomfort, and does not reflect evolving
drug resistance patterns.
In the past decade, shorter duration regimens for the
treatment of DS-TB have been explored, and two new
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drugs specifically developed for MDR-TB – bedaquiline
(BDQ) and delamanid (DLM) – have recently been intro-
duced. There is however, little evidence about their opti-
mal use. There are also other new drugs in development
as well as investigational regimens using combinations of
new and repurposed drugs [6]. Clinical trials of a number
of experimental regimens against MDR-TB are currently
underway or being planned (Table 1).
Recognizing the unique opportunity presented by these
recent, exciting developments, and the synergies that
could be realized through consensus and coordination
among stakeholders involved in these MDR-TB trials,
TREAT TB (Technology, Research, Education, and
Technical Assistance for Tuberculosis) – a USAID-
funded, Union-implemented research initiative – and
RESIST-TB (Research Excellence to Stop TB Resistance)
co-hosted the first Global MDR-TB Clinical Trials
Landscape Meeting in December, 2014. The meeting
was held simultaneously in Washington, D.C. and Cape
Town, South Africa. Key issues addressed included
composition of regimens, methodological challenges for
evaluating new drug regimens, standardization of trial
definitions, and mechanisms for communication and
coordination among trials groups.
Table 1 Summary of Experimental Regimens in MDR-TB Clinical Trials Underway or Planned
Trial Name (funding
source)
Duration of Experimental
Regimen (months)
Comparator Experimental Arm(s) GOAL
Shorten All-
oral
Improve
tolerability
Improve
cure rates
C 213/Phase 3
Delamanid (Otsuka)
24 WHO Std DLM + OBT X
NeXT (MRC-SA) 6-9 SA Std BDQ+LZD+LFX+ETA/INHH
+PZA
X X X
endTB (PIH-MSF) 9 WHO Std (+/-
new drug)
BDQ+LZD+MXF (HD)+PZA
BDQ+CFZ+LZD+LFX+PZA
DLM+LZD+MXF (HD)+PZA
DLM+CFZ+LZD+LFX+PZA
DLM+CFZ+MXF+PZA
X X X X
TB-PRACTECAL (MSF) 6 WHO Std (+/-
new drug)
BDQ+PRT+LZD+MXF
BDQ+PRT+LZD+CFZ
BDQ+PRT+LZD
X X X X
STREAM
Stage 1
(USAID+)
9 WHO Std CFZ+EMB+MXF+PZA+4(KM
+INHH+PTO)
X X
STREAM
Stage 2
(USAID+)
6:
9:
WHO Std
9 mo. Regimen
BDQ+LFX+CFZ+PZA+2(INHH
+KM)
BDQ+CFZ+EMB+LFX+PZA+4
(INHH+PTO)
X X X
NC-005* (GATB) 2 None for MDR
Arm
BDQ+PRT+MXF+PZA
Note: this is a phase 2 study
in DS & MDR-TB
X X X X
NiX-TB 6-9 None BDQ+PRT+LZD X X X X
STAND* (GATB) 4-6 None for MDR
Arm
PRT+MXF+PZA X X X X
Novartis 24 WHO Std CFZ+OBT X
Opti-Q 6 LFX 11 mg/kg +
OBT
LFX 14, 17 ands 20 mg/kg
(all + OBT)
X
BDQ - Bedaquiline
CFZ - Clofazimine
DLM – Delamanid
EMB – Ethambutol
INH - Isoniazid
LFX - Levofloxacin
LZD – Linezolid
MXF – Moxifloxacin
PRT- Pretomanid (PA-824)
PZA - Pyrazinamide
OBT= optimized background therapy
HD=high dose
*Primarily DS-TB study with nonrandomized comparator MDR-TB arm; patients with PZA or MXF resistance excluded
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Overarching issues in MDR-TB trial design
Clinical trials to evaluate drugs and regimens for treat-
ment of MDR-TB are more complex and less easy to
standardize than clinical trials of drug-susceptible TB.
These complexities result in some issues specific to
designing MDR-TB trials include:
• Weight of evidence required to change policy and
practice. For example, given the urgent need to
develop MDR-TB regimens, it might be justifiable to
accept one small, well-controlled RCT, or make con-
cessions with regard to the choice of control, statistical
adjustment for multiplicity, etc.
• Maintaining flexibility within the trial design so that
it can be adapted to external data developed while the
trial is in progress, thus ensuring that trial results
retain relevance when they are published. Bayesian
adaptive randomization is one possible approach to
the design of efficient multi-arm trials [7]. This
approach has been used most often in oncology trials.
Initial randomization probabilities are fixed among
arms. Probability of a treatment effect estimated
through interim analysis of data (sometimes using a
surrogate marker) affects subsequent assignments.
This enables 1) increased randomization to study
arms that show improved performance, and 2) dis-
continuation of arms that are ineffective or unsafe.
Compared to fixed randomization, Bayesian adaptive
randomization results in a reduction in overall sample
size requirements to detect a specified effect size.
• Selecting the appropriate patient population. For
MDR-TB regimens to be effective on a population
level, they will need to work across a range of patterns
of resistance to anti-TB drugs and of co-morbidities.
Study populations will need to reflect this heterogene-
ity so eligibility criteria should be minimally restrictive.
• Choice of control regimen. Although the internal
control is considered fundamental to the randomized
trial, there is currently no universal standard of care,
and treatment standards may change over time.
Control options might include the locally used regi-
men based on the WHO guidelines or (a variant of)
one of the shortened regimens that has yielded suc-
cess in Bangladesh and West Africa [8-10].
• Duration and frequency of follow up. Introduction of
new regimens entails concerns about possible toxicity
and, for shortened regimens, increased risk of relapse.
Establishing standard or minimum duration and fre-
quency of follow up is necessary to produce compar-
able results across trials. Since regimens being
evaluated are of different durations, selection of a fixed
amount of time for post-treatment follow up may not
permit comparison of regimens within and between
trials. Establishing a minimum duration of follow up
relative to time since randomization—rather than after
treatment—may represent the most practical solution.
There are, however, limited data on the timing of
relapse after treatment for MDR-TB so the length of
this period cannot be determined based on substantial
evidence. This issue is discussed in more detail below.
• Safety monitoring. For new drugs, intensive safety
monitoring is needed but the interpretation of
results of such monitoring must be made in light of
the distinctly different risk-benefit balance between
efficacy and toxicity compared to existing drugs for
DS-TB.
Regimen design issues
Shortening the overall duration of treatment
Shortening the duration of TB treatment could dramati-
cally improve adherence and thus minimize the develop-
ment of resistance, as well as lower the costs of therapy.
However, determining the appropriate duration of ther-
apy has proven challenging since the nature of the rela-
tionship between bacteriological endpoints in the first
2-3 months of treatment (usually culture conversion on
solid media) and long-term outcomes is poorly under-
stood. Murine relapse studies and stratified approaches
also have thus far failed to clarify treatment duration for
MDR-TB. In general, MDR-TB regimens are less potent
than DS-TB regimens and require more time to achieve
stable culture conversion. Most data on treatment
response in MDR-TB have been obtained in observa-
tional cohort studies. A recent meta-analysis of these
studies found that treatment duration of 7-8.5 months
in the initial phase, with a total duration of 25-27
months yielded the highest odds of success [11], yet the
authors of this study emphasized the “serious limita-
tions” of these observational data and the urgent need
for RCTs that assess the optimum treatment duration.
Establishing a common global framework that encom-
passes data from DS and MDR-TB clinical trials in
order to identify intermediate endpoints would enable
comparison of drug class-specific effects and the efficacy
of different regimens. Although two- or three-month
culture conversion has shown promise as a possible sur-
rogate endpoint, variability among different studies sug-
gests that a summary measure of culture conversion
over time may hold more potential as a surrogate [12].
While shorter duration treatment may be sufficient for
the majority of patients, a minority of patients will relapse.
However, it may be possible to identify subpopulations
likely to relapse by mining existing datasets and analyzing
new studies to determine baseline and on-treatment char-
acteristics, and interim endpoints that correlate with
relapse. These data may also enable predictive modeling.
Unfortunately, currently available retrospective observa-
tional data sets disproportionately contain data on patients
Mitnick et al. BMC Proceedings 2015, 9(Suppl 8):S1
http://www.biomedcentral.com/1753-6561/9/S8/S1
Page 3 of 8
treated for 20-24 months, and thus provide little data on
whether shortened regimens might have acceptable relapse
rates.
Conversely, children, and other sub-populations prone
to have lower bacillary burdens, could be particularly well
suited for shortened regimens. Since current regimens—
including presentation and dosing—are not optimized for
children, it would be particularly valuable to concurrently
explore treatment shortening for pediatric patients and for
adults.
It may also be possible to optimize treatment regimen
concurrently with shortening the duration of treatment.
Innovative trial designs, e.g., adaptive designs, may facili-
tate such studies, but will require additional capacity. Any
studies should also be accompanied by cost analyses, as
well as other policy-related efforts to ensure uptake of
shorter regimens.
Eliminating injectable agents from the regimen
Current recommended MDR-TB treatment regimens
require daily painful injections for 8 months, requiring
considerable infrastructure and investment in nurse and
patient time; associated ototoxicity is substantial and
irreversible. Moreover, resistance to injectable drugs
(kanamycin, amikacin, and capreomycin) is increasing
[13]. All-oral treatment offers potential advantages in
terms of decentralized, community-based delivery and
fewer injection-related adverse events [6]. The opportu-
nity to provide all-oral treatment is now possible with
the recent introduction of DLM and BDQ. Current con-
straints to their use include the fact that these drugs
have yet to be optimized within a background regimen.
Safety concerns about the combination of BDQ and
DLM will be addressed with a combination PK study
since both classes of drugs have been associated with
QT prolongation. Nevertheless, other advances with
existing oral drugs—such as late-generation fluoroquino-
lones, clofazimine (CFZ), linezolid (LZD), and pyrazina-
mide (PZA)—including increased dosing and shortened
regimens, also support the potential for effective all-oral
regimens.
The endTB project (Expand New Drug Markets for TB)
is planning a phase III randomized (adaptive) open-label
trial to optimize all-oral regimens by combining BDQ or
DLM with CFZ, LZD, a fluoroquinolone (moxifloxacin or
levofloxacin) and PZA. endTB will test regimens with one
new drug; further investigation of combinations with both
BDQ and DLM may be indicated after the aforementioned
combination study (NIAID, ACTG Protocol A5343). In
endTB, subjects will be randomized to 6 arms. Interim
analyses will guide adaptation of randomization, favoring
most effective arms. Study assessments will strongly
emphasize safety. One important issue that arose in study
design was the choice of control (see “Next steps to
advance regimen development for MDR-TB”).
Questions persist about the best oral agents to replace
injectables since the quality of evidence is low supporting
the role of injectables in MDR-TB treatment. Moreover,
there is heterogeneity in the response to these drugs. Data
from MDR-TB observational cohorts may also be mined
to provide guidance for optimal design of injectable-free
regimens.
New animal studies could inform the substitution
choices, by further elucidating the mechanisms of action
of injectable and oral agents. Eliminating injectable agents,
it was noted, may not be feasible for all patients. Options
could be considered such as the use of alternative routes
of delivery of these drugs (e.g., inhalation) or shortening
the period of injectable administration when a new or
repurposed drug is added to the regimens.
Provision of adequate evidence
WHO’s mandate to provide normative guidance for
countries has been reflected in a number of recent
documents. In 2012, a strategic roadmap was developed
by WHO to guide the global development of new drugs
and drug regimens for the treatment of DS and DR-TB.
WHO subsequently developed a policy implementation
package (PIP) to guide introduction of new TB drugs
and two interim guidance documents on the use of
BDQ (June 2013) [14] and DLM (Oct 2014) [15] in the
treatment of MDR-TB. These documents address key
issues regarding the use of new drugs and regimens:
what is the added value and anticipated impact of the
new drugs or regimens, what populations would most
benefit, and what are the possibilities for optimal
deployment of these new drugs or regimens in various
countries. Designs of trials to evaluate new drugs and
regimens must ensure that the evidence they generate
will provide an adequate basis for approval by regulatory
agencies and practice guideline panels.
In recognition that a series of trials have been initiated
or are about to start investigating combination regimens,
including new or re-purposed drugs, for the treatment of
MDR-TB, WHO is preparing an information note on
MDR-TB regimen development describing the evidence
and trial documentation they will require to develop or
update policy recommendations on the treatment of
MDR-TB. Data from preclinical, pharmacokinetic/ phar-
macodynamic (PK/PD), drug-drug interaction (DDI), and
clinical studies will be considered to contribute to the
evidence base. Results from these studies will be evalu-
ated using the GRADE (Grading of Recommendations,
Assessment, Development, and Evaluation) system [16].
This approach requires evaluation of the study design,
number of studies done, and other characteristics in
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order to determine the quality of evidence and the
strength of the recommendation. The information note is
currently in draft form, with WHO seeking feedback
from experts in the field and drug developers regarding
the proposed framework.
Consideration of specific antimycobacterial
agents with likely important roles in new
regimens
Prior to the workshop, six anti-tuberculosis drugs were
identified as particularly important for improved treat-
ment of MDR-TB. Criteria for selection included evi-
dence of antimycobacterial efficacy, being new (approved
or in late stages of clinical development); being drugs to
which populations have had limited prior exposure; or
being so important to efficacy of current MDR-TB regi-
mens that their exclusion seems ill-advised. The drugs
selected for review at the workshop were bedaquiline,
fluoroquinolones, delamanid, oxazolidinones, clofaza-
mine, and pretomanid). The advantages and challenges
of using these drugs are summarized below.
Bedaquiline (BDQ), an ATP synthase inhibitor, was
conditionally approved by the U.S. Food and Drug Admin-
istration (FDA) in 2013 and by the European Medicines
Agency (EMA) in 2014 for the treatment of MDR-TB. It is
active against both DS and MDR strains of M. tuberculosis,
with strong bactericidal and sterilizing properties. The
WHO and CDC recommend its use in patients with
MDR-TB who cannot be treated with a minimum of three
effective drugs [17]. Common adverse effects include nau-
sea, joint pain and headache. There are also concerns
about prolongation of the QT interval on electrocardio-
gram and hepatic toxicity [18].
A number of unanswered questions about BDQ need to
be better understood as the drug becomes more widely
used in clinical practice. In particular, non-target-based
resistance and efflux-based resistance, as well as cross-
resistance with clofazimine (CFZ) may limit the usefulness
of BDQ in clinical practice. Resistance is already develop-
ing to BDQ, pointing to the need for robust regimens that
protect against emergence of resistance and strategies to
promote compliance.[19]
Fluoroquinolones. Fluoroquinolones (FQs) are a class of
broad-spectrum antibiotics that inhibit the DNA gyrase
enzyme, which is essential for bacterial replication. They
are among the most effective drugs used to treat MDR-
TB. While these drugs have excellent early bactericidal
activity, they lack sterilizing activity and thus need to be
given in combination with sterilizing agents. The class
member thought to be most potent (moxifloxacin) can
prolong the QT interval, as can other TB drugs of interest
for novel regimens. Consequently, their safety in combina-
tion therapy must be further evaluated. Resistance and
cross-resistance have also emerged as major concerns. In
addition, the optimal dose of the most effective fluoroqui-
nolones – moxifloxacin and levofloxacin – has not yet
been determined either as single agents, in combination
regimens, or for treating latent infections.
Three types of studies were proposed to evaluate the
optimal dose of fluoroquinolones in combination with
optimal background therapy or with other backbones for
the treatment of MDR-TB. An optimal dose study could
test fixed doses (e.g., 400, 600, or 800 mg) or mg/kg
doses for PK/PD, safety, tolerability, and effectiveness. A
combination study would test whether fluoroquinolones
can or should be given in combination with other drugs
that prolong the QT interval through dose optimization
studies with different backbone regimens. The third sug-
gested type of study would evaluate the optimal regimen
for prevention of MDR-TB in close contacts of patients
with MDR-TB.
Delamanid. Delamanid (DLM) is a novel anti-TB agent
of the nitroimidazole class that inhibits the synthesis of
mycolic acid, a component of the cell wall and envelope of
M. tb. It was registered by the EMA, Japan’s PMDA, Kor-
ea’s MFDS, and will be submitted to the U.S. FDA in 2015
or 2016 for the treatment of MDR-TB. Two clinical stu-
dies of efficacy and safety indicated improved outcomes,
including lower mortality, with long-term (≥ 6 months)
compared to short-term (≤ 2 months) DLM treatment,
when added to optimized background therapy for 12-18
months [20-22]. Recipients of delamanid had more QT
prolongation than those receiving placebo. There is no
reported cross-resistance to existing anti-TB drugs.
Studies underway will test the effectiveness of DLM
combination with moxifloxacin and other agents in HIV
uninfected and coinfected patients. A pediatric formula-
tion of DLM has also been developed and is being tested.
As noted, ACTG study A5343 will assess drug-drug
interactions between DLM and BDQ.
Oxazolidinones. Oxazolidinones are protein-synthesis
inhibitors that prevent bacteria from growing and repro-
ducing. The first-in-class linezolid (LZD) was approved in
2000 for the treatment of drug resistant bacterial infec-
tions and has demonstrated effectiveness in DR-TB. Sev-
eral new oxazolidinones are in development (sutezolid,
AZD 5847, tedizolid, and radezolid.) LZD can be com-
bined with other TB drugs, has high oral bioavailability,
pharmacodynamics that permit once-daily dosing, and has
a low propensity for resistance emergence [23]. However,
long-term use has been limited by toxicity, particularly
myelosuppression and myelopathy.
Clinical and non-clinical studies suggest that intermit-
tent dosing could avert LZD-associated toxicity while
retaining efficacy. Further investigation is necessary to
confirm this relationship and optimize the dosing regimen.
Studies are also needed to determine whether higher doses
required to suppress resistance could be achieved through
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intermittent dosing. With regard to new-generation oxa-
zolidinones, murine studies suggest that sutezolid may
have more potency against intracellular M. tb. and that
other drugs in this class have additive effects when com-
bined with regimens including BDQ, PA-824, and PZA
[24,25].
Clofazimine. Clofazimine (CFZ) is one of the older
TB drugs, approved for the treatment of leprosy and
more recently, used off-label for MDR-TB [26]. It binds
to DNA to disrupt bacterial grown and also has anti-
inflammatory activities. It has been tested in several
MDR-TB regimens designed to shorten treatment
[8-10,27], and is also being included in other treatment
shortening programs including the STREAM, TB PRAC-
TECAL and endTB trials (Table 1). Novartis is now
designing a study to demonstrate the intrinsic activity of
CFZ against M.tb., as well as to fill in the gaps in toxi-
cology, safety, PK/PD, mechanisms of action, and drug
resistance. There may also be opportunities to use CFZ
in pediatric regimens.
Pretomanid.Pretomanid (PA-824), a nitroimidazole, is
a novel anti-bacterial compound developed by the TB
Alliance (TBA) with significant bactericidal and steriliz-
ing activity alone and in combination with BDQ and
PZA [24]. It is a pro-drug with a novel, complex, and
incompletely understood mechanism of action [28].
Designed to enable a simple dosing schedule, short treat-
ment duration, good side-effect profile, and minimal
interaction with anti-retrovirals, it is being tested in mul-
tiple MDR-TB regimens including the STAND Phase 3,
NC005, and Nix-TB (in patients with XDR-TB) studies
(Table 1). PA-824 is also being studied in an MDR-TB
treatment trial by Médecins Sans Frontières (MSF), the
TB-PRACTECAL study, also shown in Table 1.
Table 1 summarizes experimental regimens for MDR-
TB in current or planned clinical trials. These trials have
been designed to achieve different goals, e.g., shortening
treatment, providing an all-oral regimen, improving toler-
ability, or improving cure rates.
Next steps to advance regimen development for
MDR-TB
Progress in developing more effective regimens for MDR-
TB will require continued international collaboration
among stakeholders, an outcome that will hopefully be
advanced by the Global MDR-TB Clinical Trials Landscape
Meeting. Participants agreed on the need to focus efforts in
a number of key areas:
Standardization of MDR-TB definitions
For harmonization across trials, standardization of interim
and post-treatment endpoints is critical. Definitions have
been proposed by the WHO [20], FDA [29] and EMA[30],
and consensus research outcomes definitions for MDR-TB
have been proposed for drug-resistant TB in children [31].
However, there remains a need for universally accepted
definitions. A multi-national group of TB clinical trials
investigators has proposed consensus definitions for effi-
cacy endpoints (culture conversion, death, unfavorable
outcome, favorable outcome, cure, treatment failure,
recurrence/reinfection, and recurrence/relapse); tolerance
and adherence endpoints (“lost to follow up”, treatment
discontinuation/modification, and inadequate adherence);
safety endpoints; standard of care; optimized background
therapy. The team has also discussed preferences regard-
ing solid or liquid culture, molecular tests, length of fol-
low-up period, managing drugs with long half-lives,
predictor variables, and pediatric considerations. A
RESIST-TB collaborative group developed a consensus
document addressing these issues and this manuscript is
currently under review.
Building MDR-TB trial capacity
In order to be ready for complex combination trials in the
future, increased clinical trial capacity—both sites and
potential participants—is necessary. Including adolescents
in adult trials could be one means of increasing the num-
ber of available subjects. Adolescents have adult-type dis-
ease and metabolize drugs similarly to adults. Building
MDR-TB observational cohorts in a broad range of loca-
tions, and establishing networks of sites, could provide
trial-ready sites and subjects when needed. Community
engagement will be essential to this effort. Efforts should
also be made to incentivize treatment programs seeing
patients with MDR-TB to participate in prospective MDR-
TB observational cohort studies. RESIST-TB has devel-
oped site development tools and has volunteered to serve
as a repository for observational cohort data.
Implementing adjunct measures to enhance
clinical benefits of introducing new drugs
As new drugs are introduced, it will be important to
optimize their use and avoid emergence of resistance
through a combination of:
• Development of more robust companion regimens
• Incorporation of efflux pump inhibitors and other
novel agents in regimens
• Roll-out of drug susceptibility testing for the new
agents
• Trials of preventive therapy for MDR-TB contacts
• Identification of super spreaders [32] with DR-TB,
combined with isolation and/or treatment with
aggressive regimens for such patients.
• Development and roll-out of rapid tests for drug
susceptibility.
• Development of improved outcome measures for
comparing the efficacy of regimens in different
Mitnick et al. BMC Proceedings 2015, 9(Suppl 8):S1
http://www.biomedcentral.com/1753-6561/9/S8/S1
Page 6 of 8
populations; for example, time to positivity in
MGIT (mycobacterial growth indicator tube) and
more uniform approaches to the interpretation of
chest radiographs.
• Therapeutic drug monitoring for new drugs.
• Development and implementation of strategies to
foster adherence to MDR-TB regimens.
Developing tools to predict failure and relapse
Tools are needed to predict failure and relapse at both the
patient level and treatment arm level in clinical trials. For
example, change in time to positivity in MGIT combined
with baseline bacillary load may identify patients at the
highest risk of relapse. Studies have indicated that it is
possible to stratify patients into those at very high risk of
relapse; however, translating this into an operational strat-
egy remains a challenge. Moreover, predictors of relapse
in MDR-TB may not be the same as those in DS-TB.
Improving outcomes by understanding adherence
and social determinants of success
Few, if any, studies build social determinants into clinical
trial protocols. This represents a lost opportunity since
social factors may explain some of the heterogeneity in
treatment outcomes both within and between treatment
arms. Gathering such information in the context of trials
could provide valuable information about interventions
that might optimize treatment outcomes across patients
of different socio-economic status.
Challenges in common control regimens
Several issues emerged with regard to the control regi-
men. First, since the current WHO regimen is widely
perceived as suboptimal, there are ethical concerns about
including this as a control. Second, in some countries
such as South Africa, BDQ use may soon be increasing
for MDR-TB treatment, at least for HIV-negative
patients; however, BDQ is still not available in most
high-burden MDR-TB countries. Consistency in the
selection of controls across sites and trials would enable
data to be combined and compared. Given the differ-
ences in standard of care in different countries and
regions, however, this may not be feasible. Further, the
definition of an optimized background regimen may
change during the course of a trial, in the face of emer-
ging evidence. The discussions highlighted the obstacles
that exist now and likely in the future in identifying a
uniform control regimen across trials.
Treating MDR-TB in special populations, including
children and patients co-infected with HIV
Worldwide, about 13% of people with TB are also
co-infected with HIV; about 78% of these cases are from
the African region [1]. The co-occurrence of these two
infections results in more severe disease and increased
mortality, yet little is known about the treatment of MDR-
TB in the context of HIV infection, including among
pediatric patients. Thus, workshop participants agreed on
the need to focus research on the implications of co-infec-
tion. Identifying and assessing issues specific to pediatric
patients is especially needed.
Conclusions
Meeting participants agreed that the issues discussed at
the meeting and summarized in this report need to be
pursued, and that agreement on a number of core issues
would facilitate making timely progress towards improved
treatment and control of the global MDR-TB epidemic.
Participants agreed to work together through RESIST-TB
(http://www.resisttb.org) and other fora to move the field
forward. A follow-up meeting is planned for Spring 2016
to assess progress toward these goals, facilitate continued
communication among trials groups and consider addi-
tional initiatives to accelerate this process.
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